{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:14:41Z","timestamp":1783574081870,"version":"3.55.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Evidence regarding lusutrombopag use in patients with hepatocellular carcinoma (HCC) and poor hepatic reserve remains limited, particularly in ALBI grade 3 patients. This study aimed to explore peri-procedural platelet outcomes after lusutrombopag treatment in HCC patients stratified by ALBI grade, with particular attention to the ALBI grade 3 subgroup.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a single-center retrospective study of 76 patients with HCC and thrombocytopenia who received lusutrombopag before planned procedures. Patients were stratified as ALBI grades 1\u20132 or ALBI grade 3. The primary endpoint was peri-procedural platelet count, defined as the platelet on the procedure day or the closest available value within a \u00b12-day window. Exploratory analyses included an adjusted general linear model, logistic regression for non-response, and per-protocol sensitivity analyses excluding patients who received rescue therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 76 patients, 58 had ALBI grades 1\u20132 and 18 had ALBI grade 3. The primary endpoint was evaluable in 60 patients, including 46 with ALBI grades 1\u20132 and 14 with ALBI grade 3. Median peri-procedural platelet counts were 59.0 (50.0\u201369.0) \u00d7 10\n                      <jats:sup>9<\/jats:sup>\n                      \/L in the ALBI grades 1\u20132 group and 69.0 (41.8\u201382.8) \u00d7 10\n                      <jats:sup>9<\/jats:sup>\n                      \/L in the ALBI grade 3 group (\n                      <jats:italic>p = 0.345<\/jats:italic>\n                      ). Responder rates were 84.5% (49\/58) and 77.8% (14\/18), respectively (\n                      <jats:italic>p = 0.493<\/jats:italic>\n                      ). In adjusted analyses, ALBI grade 3 was not independently associated with lower peri-procedural platelet count or non-response after accounting for baseline platelet count and relevant covariates. Per-protocol sensitivity analyses yielded directionally similar findings. No bleeding or thrombotic events were observed in the ALBI grade 3 group, although safety analyses were descriptive.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this selected real-world HCC cohort, ALBI grade 3 was not independently associated with lower peri-procedural platelet count after lusutrombopag treatment. These findings are exploratory and should not be interpreted as evidence of equivalent efficacy or established safety across ALBI strata. Larger prospective studies are needed to validate these results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1817055","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:20:02Z","timestamp":1783570802000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Platelet optimization in high-risk ALBI grade 3 patients undergoing invasive procedures: real-world evidence from lusutrombopag therapy"],"prefix":"10.3389","volume":"17","author":[{"given":"Kongcai","family":"Zhu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Beijing Youan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Xiong","sequence":"additional","affiliation":[{"name":"Department of Oncology, Beijing Youan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haihong","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Youan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Youan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1067\/mcp.2002.121829","article-title":"Changes in plasma protein binding have little clinical relevance","volume":"71","author":"Benet","year":"2002","journal-title":"Clin. Pharmacol. Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"100347","DOI":"10.1016\/j.jhepr.2021.100347","article-title":"ALBI grade: evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma","volume":"3","author":"Demirtas","year":"2021","journal-title":"JHEP Rep."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e16342","DOI":"10.7759\/cureus.16342","article-title":"Thrombocytopenia in chronic liver disease: challenges and treatment strategies","volume":"13","author":"Desai","year":"2021","journal-title":"Cureus"},{"key":"B4","doi-asserted-by":"publisher","first-page":"4285","DOI":"10.1007\/s12325-022-02237-8","article-title":"Pharmacokinetic assessment and treatment effect of lusutrombopag in child-pugh class C patients: review of patient data from two clinical studies and post-marketing surveillance","volume":"39","author":"Flamm","year":"2022","journal-title":"Adv. Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.3390\/jcm13133965","article-title":"Final results from the first European real-world experience on lusutrombopag treatment in cirrhotic patients with severe thrombocytopenia: insights from the REAl-World lusutrombopag treatment in ITalY study","volume":"13","author":"Gallo","year":"2024","journal-title":"J. Clin. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.tracli.2022.08.147","article-title":"Platelet transfusion in adults: an update","volume":"30","author":"Garraud","year":"2023","journal-title":"Transfus. Clin. Biol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.cgh.2018.11.047","article-title":"Lusutrombopag reduces need for platelet transfusion in patients with thrombocytopenia undergoing invasive procedures","volume":"17","author":"Hidaka","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","article-title":"Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade","volume":"33","author":"Johnson","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s00228-018-2599-x","article-title":"Pharmacokinetics of free and total mycophenolic acid in adult lupus nephritis patients-implications for therapeutic drug monitoring","volume":"75","author":"\u0141uszczy\u0144ska","year":"2019","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"285","DOI":"10.7326\/0003-4819-127-4-199708150-00005","article-title":"Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation","volume":"127","author":"Martin","year":"1997","journal-title":"Ann. Intern Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/HMER.S74612","article-title":"The pathophysiology of thrombocytopenia in chronic liver disease","volume":"8","author":"Mitchell","year":"2016","journal-title":"Hepat. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1186\/s12876-020-01573-9","article-title":"Lusutrombopag is effective and safe in patients with chronic liver disease and severe thrombocytopenia: a multicenter retrospective study","volume":"20","author":"Nomoto","year":"2020","journal-title":"BMC Gastroenterol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1111\/liv.13317","article-title":"Thrombocytopenia in chronic liver disease","volume":"37","author":"Peck-Radosavljevic","year":"2017","journal-title":"Liver Int."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1002\/hep.30561","article-title":"Lusutrombopag for the treatment of thrombocytopenia in patients with chronic liver disease undergoing invasive procedures (L-PLUS 2)","volume":"70","author":"Peck-Radosavljevic","year":"2019","journal-title":"Hepatology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jhep.2016.09.008","article-title":"The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma","volume":"66","author":"Pinato","year":"2017","journal-title":"J. Hepatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1111\/hepr.13392","article-title":"Safety and effectiveness of lusutrombopag in Japanese chronic liver disease patients with thrombocytopenia undergoing invasive procedures: interim results of a postmarketing surveillance","volume":"49","author":"Sasaki","year":"2019","journal-title":"Hepatol. Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.3390\/jcm10071530","article-title":"Thrombocytopenia and hemostatic changes in acute and chronic liver disease: pathophysiology, clinical and laboratory features, and management","volume":"10","author":"Scharf","year":"2021","journal-title":"J. Clin. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"B19","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2165\/11539220-000000000-00000","article-title":"The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients","volume":"50","author":"Ulldemolins","year":"2011","journal-title":"Clin. Pharmacokinet."},{"key":"B20","volume-title":"Mulpleta (Lusutrombopag) Prescribing Information","year":"2018"},{"key":"B21","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1159\/000510692","article-title":"Impact of anti-GPIIb\/IIIa antibody-producing B cells as a predictor of the response to lusutrombopag in thrombocytopenic patients with liver disease","volume":"39","author":"Wada","year":"2021","journal-title":"Dig. Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e658","DOI":"10.3747\/co.26.5423","article-title":"Clinical practice guideline for image-guided multimode tumour ablation therapy in hepatic malignant tumours","volume":"26","author":"Wang","year":"2019","journal-title":"Curr. Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1111\/hepr.13945","article-title":"Safety and effectiveness of lusutrombopag in patients who have chronic liver disease with thrombocytopenia and undergoing invasive procedures: real-world post-marketing surveillance in Japan","volume":"53","author":"Yoshiji","year":"2023","journal-title":"Hepatol. Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/jrmt.jrmt_2_24","article-title":"The value of portal vein diameter in evaluation of chronic liver disease","volume":"5","author":"Yunusa","year":"2024","journal-title":"J. Radiol. Med. Technol. Trop."},{"key":"B25","doi-asserted-by":"publisher","first-page":"539","DOI":"10.21037\/atm.2020.02.85","article-title":"Comparison between child-pugh score and Albumin-Bilirubin grade in the prognosis of patients with HCC after liver resection using time-dependent ROC","volume":"8","author":"Zhao","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"28350","DOI":"10.1038\/s41598-024-79416-w","article-title":"Safety of local thermal ablation in hepatocellular carcinoma patients with cirrhosis and severe thrombocytopenia","volume":"14","author":"Zhao","year":"2024","journal-title":"Sci. Rep."},{"key":"B27","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1159\/000546574","article-title":"China liver cancer guidelines for the diagnosis and treatment of hepatocellular carcinoma (2024 edition)","volume":"14","author":"Zhou","year":"2025","journal-title":"Liver Cancer"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1817055\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:20:03Z","timestamp":1783570803000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1817055\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":27,"alternative-id":["10.3389\/fphar.2026.1817055"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1817055","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"article-number":"1817055"}}